Alan FairlambJump to: navigation, search File:TSH.png Trypanothione. The glutathione moieties are shown in black and the polyamine linker in red.
Alan Hutchison Fairlamb CBE, FRSE, FLS (born 30 April 1947, Newcastle upon Tyne, England) is a Wellcome Principal Research Fellow, Professor of Biochemistry and Head of the Division of Biological Chemistry and Drug Discovery at the University of Dundee, Scotland. He is also a member of the Scientific and Technical Advisory Committee of the Special Programme for Research and Training in Tropical Diseases (TDR) -- an independent global programme of scientific collaboration co-sponsored by UNICEF, UNDP, the World Bank and WHO.
Professor Alan Fairlamb and his team study the protozoan parasites causing three different diseases - sleeping sickness, Chagas disease and leishmaniasis. He was one of the 250 scientists involved in the genome sequencing of these parasites.
In 1985, Alan Fairlamb discovered an unique thiol compound present in these parasites, and named it trypanothione. This thiol metabolite is quite different from its human equivalent, glutathione. Trypanothione allows the parasites to fend off free radicals and other toxic oxidants produced by the immune system of the infected patient, and was shown to be vital for parasite survival and virulence. For instance, antimonials neutralize the Leishmania parasite’s antioxidant defence system, allowing the patient to clear the infection.
Since 2006, Alan Fairlamb has been co-director of the Drug Discovery Unit at the University of Dundee. The new centre, opened in 2005, has new facilities for high-throughput screening and medicinal chemistry. These will take the drug discovery/development process further than any other UK university, to a stage where pharmaceutical companies will have sufficient data to move into the production stage.
- ↑ Berriman M, Ghedin E, Hertz-Fowler C; et al. (2005). "The genome of the African trypanosome Trypanosoma brucei". Science. 309 (5733): 416–22. PMID 16020726. CS1 maint: Explicit use of et al. (link)CS1 maint: Multiple names: authors list (link)
- ↑ Fairlamb AH, Blackburn P, Ulrich P, Chait BT, Cerami A (1985). "Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids". Science. 227 (4693): 1485–7. PMID 3883489. CS1 maint: Multiple names: authors list (link)
- ↑ Krieger S, Schwarz W, Ariyanayagam MR, Fairlamb AH, Krauth-Siegel RL, Clayton C (2000). "Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress". Mol. Microbiol. 35 (3): 542–52. PMID 10672177. CS1 maint: Multiple names: authors list (link)
- ↑ Wyllie S, Cunningham ML, Fairlamb AH (2004). "Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani". J. Biol. Chem. 279 (38): 39925–32. PMID 15252045. CS1 maint: Multiple names: authors list (link)
External Links[www.wikidoc.org]" Categories:
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Pages with broken file links
- 1947 births
- Living people
- People from Newcastle upon Tyne
- English biochemists
- Academics of the University of Dundee
- Fellows of the Royal Society of Edinburgh
- Commanders of the Order of the British Empire
Navigation WikiDoc | WikiPatient | Up To Date Pages | Recently Edited Pages | Recently Added Pictures Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Maintain Pages | What Pages Link Here | Quality Improvement
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies Tweet Follow @wikidoc
- What links here
- Related changes
- Special pages
- Printable version
- Permanent link
- Page information
- Browse properties
- This page was last edited 14:13, 4 September 2012 by wikidoc user WikiBot. Based on work by Jacki Buros (bot) and Alexandra Almonacid and wikidoc anonymous user 18.104.22.168.
- Content is available under Creative Commons Attribution/Share-Alike License unless otherwise noted; All rights reserved on Board Review content.